摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

o-cumenesulfonyl chloride | 61738-47-4

中文名称
——
中文别名
——
英文名称
o-cumenesulfonyl chloride
英文别名
2-Isopropyl-benzolsulfochlorid;2-isopropylbenzenesulfonyl chloride;2-(Propan-2-yl)benzene-1-sulfonyl chloride;2-propan-2-ylbenzenesulfonyl chloride
o-cumenesulfonyl chloride化学式
CAS
61738-47-4
化学式
C9H11ClO2S
mdl
MFCD04973902
分子量
218.704
InChiKey
VHORYVBOBIUIDS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    292.6±19.0 °C(Predicted)
  • 密度:
    1.241±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.333
  • 拓扑面积:
    42.5
  • 氢给体数:
    0
  • 氢受体数:
    2

SDS

SDS:23ab66e7a4d7ef1840c2e67715e95109
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    o-cumenesulfonyl chloride 在 KF 作用下, 以 1,4-二氧六环 为溶剂, 生成 o-cumenesulfonyl fluoride
    参考文献:
    名称:
    Perfluoroalkyl-substituted, benzoylguanidines, a process for their
    摘要:
    全氟烷基取代的苯甲酰胍啉,其制备过程,作为药物或诊断剂的用途,以及含有它们的药物。描述了公式I的全氟烷基取代苯甲酰胍啉##STR1##其中R(1)为(C.sub.1 -C.sub.6)-全氟烷基-SO.sub.m;R(2)和R(3)为H,卤素,烷基(氧基),苯氧基;R(4)和R(5)为H,烷基,卤素,CN,OR(7),NR(8)R(9),--(CH.sub.2).sub.n --(CF.sub.2).sub.o --CF.sub.3及其药理学上可接受的盐;化合物I通过将化合物II##STR2##与胍啉反应而得到,其中L是一种能够轻易发生亲核取代的脱离基。
    公开号:
    US05571842A1
  • 作为产物:
    描述:
    参考文献:
    名称:
    Perfluoroalkyl-substituted, benzoylguanidines, a process for their
    摘要:
    全氟烷基取代的苯甲酰胍啉,其制备过程,作为药物或诊断剂的用途,以及含有它们的药物。描述了公式I的全氟烷基取代苯甲酰胍啉##STR1##其中R(1)为(C.sub.1 -C.sub.6)-全氟烷基-SO.sub.m;R(2)和R(3)为H,卤素,烷基(氧基),苯氧基;R(4)和R(5)为H,烷基,卤素,CN,OR(7),NR(8)R(9),--(CH.sub.2).sub.n --(CF.sub.2).sub.o --CF.sub.3及其药理学上可接受的盐;化合物I通过将化合物II##STR2##与胍啉反应而得到,其中L是一种能够轻易发生亲核取代的脱离基。
    公开号:
    US05571842A1
点击查看最新优质反应信息

文献信息

  • Biphenylsulfonamide Endothelin Antagonists:  Structure−Activity Relationships of a Series of Mono- and Disubstituted Analogues and Pharmacology of the Orally Active Endothelin Antagonist 2‘-Amino-<i>N</i>- (3,4-dimethyl-5-isoxazolyl)-4‘-(2-methylpropyl)[1,1‘-biphenyl]-2-sulfonamide (BMS-187308)
    作者:Natesan Murugesan、Zhengxiang Gu、Philip D. Stein、Sharon Bisaha、Steve Spergel、Ravi Girotra、Ving G. Lee、John Lloyd、Raj N. Misra、Joan Schmidt、Arvind Mathur、Leslie Stratton、Yolanda F. Kelly、Eileen Bird、Tom Waldron、Eddie C.-K. Liu、Rongan Zhang、Helen Lee、Randy Serafino、Benoni Abboa-Offei、Parker Mathers、Mary Giancarli、Andrea Ann Seymour、Maria L. Webb、Suzanne Moreland、Joel C. Barrish、John T. Hunt
    DOI:10.1021/jm970872k
    日期:1998.12.1
    Substitution at the ortho position of N-(3,4-dimethyl-5-isoxazolyl) benzenesulfonamide led to the identification of the biphenylsulfonamides as a novel series of endothelin-A (ETA) selective antagonists. Appropriate substitutions on the pendant phenyl ring led to improved binding as well as functional activity. A hydrophobic group such as isobutyl or isopropoxyl was found to be optimal at the 4'-position
    N-(3,4-二甲基-5-异恶唑基)苯磺酰胺在邻位的取代导致将联苯磺酰胺鉴定为新型的内皮素-A(ETA)选择拮抗剂。苯环侧基上的适当取代导致改进的结合以及功能活性。发现疏水基团例如异丁基或异丙氧基在4'-位是最佳的。在2'-位引入氨基也导致改进的类似物。最佳的4'-异丁基取代基与2'-氨基官能团的结合提供了具有改善的ETA结合亲和力和功能活性的类似物(20,BMS-187308)。化合物20在抑制大鼠ET-1输注引起的升压作用方面也具有良好的口服活性。
  • [EN] AMINOETHYLAROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR<br/>[FR] COMPOSES AMINOETHYLAROMATIQUES PERMETTANT DE TRAITER DES TROUBLES REPONDANT A UNE MODULATION DU RECEPTEUR D3 DE LA DOPAMINE
    申请人:ABBOTT GMBH & CO KG
    公开号:WO2006040179A1
    公开(公告)日:2006-04-20
    The present invention relates to aromatic compounds of the formula (I) wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical Ra and wherein Ar may also carry 1 or 2 radicals Rb; X is N or CH; E is CR6R7 or NR3; R1 is C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated Cl-C4­-alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C4-cycloalkylmethyl, fluorinated C3-C4­-alkenyl, formyl or C1-C3-alkylcarbonyl; R1a is H, C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated C1-­C4-alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C4-cycloalkylmethyl, fluorinated C3­-C4-alkenyl, or R1a and R2 together are (CH2)n with n being 2, 3 or 4, or R1a and R2a together are (CH2)n with n being 2, 3 or 4; R2 and R2a are independently of each other H, C1-C4-alkyl or fluorinated C1-C4-alkyl or R2a and R2 together are (CH2)m with m being 1, 2, 3, 4 or 5; R3 is H or C1-C4-alkyl; R6, R7 independently of each other are selected from H, fluorine, C1-C4-alkyl and fluorinated C1-C4-alkyl or together form a moiety (CH2)p with p being 2, 3, 4 or 5; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
    本发明涉及公式(I)的芳香族化合物,其中Ar为苯基或芳香族5-或6-成员C-键合杂环基,其中Ar可能携带1个基团Ra,Ar也可能携带1个或2个基团Rb;X为N或CH;E为CR6R7或NR3;R1为C1-C4-烷基,C3-C4-环烷基,C3-C4-环烷基甲基,C3-C4-烯基,氟代的Cl-C4-烷基,氟代的C3-C4-环烷基,氟代的C3-C4-环烷基甲基,氟代的C3-C4-烯基,甲酰基或C1-C3-烷基羰基;R1a为H,C1-C4-烷基,C3-C4-环烷基,C3-C4-环烷基甲基,C3-C4-烯基,氟代的C1-C4-烷基,氟代的C3-C4-环烷基,氟代的C3-C4-环烷基甲基,氟代的C3-C4-烯基,或R1a和R2一起为(CH2)n,其中n为2、3或4,或R1a和R2a一起为(CH2)n,其中n为2、3或4;R2和R2a彼此独立为H,C1-C4-烷基或氟代的C1-C4-烷基,或R2a和R2一起为(CH2)m,其中m为1、2、3、4或5;R3为H或C1-C4-烷基;R6、R7彼此独立地选自H、氟、C1-C4-烷基和氟代的C1-C4-烷基,或一起形成一个(CH2)p的基团,其中p为2、3、4或5;以及其生理耐受的酸盐。该发明还涉及使用公式(I)的化合物或其药学上可接受的盐来制备用于治疗可用多巴胺D3受体配体治疗的医疗疾病的药物组合物。
  • 2-Alkyl/aryl sulphonyl-1,2,3,4-tetrahydro-9H-pyrido (3,4-b) indole-3-carboxylic acid esters/amides useful as antithrombotic agents
    申请人:Gaur Stuti
    公开号:US20060142322A1
    公开(公告)日:2006-06-29
    The present invention relates to antithrombotic compounds 2-alkyl aryl sulphonyl-1,2,3,4,-tetrahydro-9H-pyrido(3,4-b)indole-3-carboxylic acid esters/amides, pharmaceutically acceptable salts and compositions thereof to be used in the treatment of intravascular thrombosis such as myocardial ischemia and stroke. The compound has the following general structure wherein R represents methyl ester or amide and R 1 represents alkyl, aryl and heteroaryl moiety.
    本发明涉及抗血栓化合物2-烷基芳基磺酰基-1,2,3,4-四氢-9H-吡啶并(3,4-b)吲哚-3-羧酸酯/酰胺,其药学上可接受的盐和组合物,用于治疗血管内血栓形成,如心肌缺血和中风。该化合物具有以下一般结构,其中R代表甲酯或酰胺,R1代表烷基、芳基和杂环芳基基团。
  • Synthesis of Heteroaryl Sulfonamides from Organozinc Reagents and 2,4,6-Trichlorophenyl Chlorosulfate
    作者:James R. Colombe、J. Robb DeBergh、Stephen L. Buchwald
    DOI:10.1021/acs.orglett.5b01540
    日期:2015.6.19
    A method for the preparation of aryl and heteroaryl sulfonamides using 2,4,6-trichlorophenyl chlorosulfate (TCPC) is described. The reaction of 2-pyridylzinc reagents with TCPC resulted in 2,4,6-trichlorophenyl (TCP) pyridine-2-sulfonates, and the parent pyridine-2-sulfonate was shown to react with amines. Less electron-rich aryl- and heteroarylzinc reagents reacted with TCPC to afford sulfonyl chlorides
    描述了一种使用2,4,6-三氯苯基氯硫酸盐(TCPC)制备芳基和杂芳基磺酰胺的方法。2-吡啶基锌试剂与TCPC的反应生成2,4,6-三氯苯基(TCP)吡啶-2-磺酸盐,并且母体吡啶-2-磺酸盐显示与胺反应。较少电子富集的芳基锌和杂芳基锌试剂与TCPC反应生成磺酰氯,该磺酰氯可就地转化为磺酰胺。
  • [EN] AMINOMETHYL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR<br/>[FR] COMPOSES AROMATIQUES BICYCLIQUES AMINOMETHYLE SUBSTITUES PERMETTANT DE TRAITER DES TROUBLES REPONDANT A UNE MODULATION DU RECEPTEUR D3 DE LA DOPAMINE
    申请人:ABBOTT GMBH & CO KG
    公开号:WO2006040180A1
    公开(公告)日:2006-04-20
    The present invention relates to an aminomethyl substituted bicyclic aromatic compound of the formula (I) wherein Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered C-bound heteroaromatic radical comprising as ring member 1, 2 or 3 heteroatoms which are, independently of each other, selected from O, S and N, and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR8, where R8 is H, C1-C4-alkyl, fluorinated C1-C4-alkyl, C1-C4-alkylcarbonyl or fluorinated C1-C4-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents Ra, wherein the variable Ra has the meanings given in the claims and in the description; X is a covalent bond or N-R2, CHR2, CHR2CH2, N or C-R2; Y is N-R2a, CHR2a, CHR2aCH2 or CHR2aCH2CH2; is a single bond or a double bond; E is CH2 or NR3; R1 is H, C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated C1­-C4-alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C4-cycloalkylmethyl, fluorinated C3­-C4-alkenyl, formyl or C1-C3-alkylcarbonyl; R1a is H, C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-alkenyl, fluorinated C1-C4-alkyl, fluorinated C3­-C4-cycloalkyl, fluorinated C3-C4-alkenyl, R2 and R2a each independently are H, CH3, CH2F, CHF2 or CF3 or R1a and R2 or R1a and R2a together are (CH2)n with n being 1, 2 or 3; R3 is H or C1-C4-alkyl; R4 and R5 independently of each other are H, C1-C4-alkyl, fluorinated C1-C4-alkyl or C1-C4­-alkoxy or may form, together with N, a 4-, 5- or 6-membered saturated or unsaturated ring; R6 and R7 independently of each other are H or halogen; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
    本发明涉及一种氨甲基取代的双环芳香化合物,其化学式为(I),其中Ar是从苯基、一个含有1、2或3个杂原子的5-或6成员C-键合杂芳基组成的环状基团中选择的循环基团,这些杂原子独立地选择自O、S和N,以及与饱和或不饱和的5-或6成员碳环或杂环融合的苯环,其中杂环包括作为环成员的1、2或3个选自N、O和S的杂原子和/或每个独立选择自NR8的1、2或3个含杂原子的基团,其中R8为H、C1-C4-烷基、氟代C1-C4-烷基、C1-C4-烷基酰基或氟代C1-C4-烷基酰基,环状基团Ar可能携带1、2或3个取代基Ra,其中变量Ra具有权利要求和描述中给定的含义;X是共价键或N-R2、CHR2、CHR2CH2、N或C-R2;Y是N-R2a、CHR2a、CHR2aCH2或CHR2aCH2CH2;是单键或双键;E是CH2或NR3;R1是H、C1-C4-烷基、C3-C4-环烷基、C3-C4-环烷基甲基、C3-C4-烯基、氟代C1-C4-烷基、氟代C3-C4-环烷基、氟代C3-C4-环烷基甲基、氟代C3-C4-烯基、甲酰基或C1-C3-烷基酰基;R1a是H、C1-C4-烷基、C3-C4-环烷基、C3-C4-烯基、氟代C1-C4-烷基、氟代C3-C4-环烷基、氟代C3-C4-烯基,R2和R2a各自独立地为H、CH3、CH2F、CHF2或CF3,或者R1a和R2或R1a和R2a一起为(CH2)n,其中n为1、2或3;R3为H或C1-C4-烷基;R4和R5独立地为H、C1-C4-烷基、氟代C1-C4-烷基或C1-C4-烷氧基,或者与N一起形成4、5或6成员饱和或不饱和环;R6和R7独立地为H或卤素;以及其生理耐受的酸盐加合物。该发明还涉及使用化合物(I)或其药学上可接受的盐制备用于治疗对多巴胺D3受体配体治疗敏感的医疗紊乱的药物组合物。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐